Prosecution Insights
Last updated: November 20, 2026

Kaitlyn L Minchella, USPTO Patent Examiner

Listed by the USPTO as MINCHELLA, KAITLYN L

Tech Center 1600 • Art Units: 1631 1672 1682 1685

This examiner grants 27% of resolved cases

Analysis

MINCHELLA, KAITLYN L is assigned to Tech Center 1600 and Art Unit 1631. The profile includes 167 resolved cases, a 26.9% allowance rate, and a median of 1620 days to allowance. The interview lift is 20.7%, indicating a higher allowance outcome for cases associated with interviews in the reported data. Applicants may therefore evaluate interviews as one tool within a broader strategy for addressing difficult examination issues.

The principal companies are Tempus AI Inc., The Johns Hopkins University, and University of Maryland, Baltimore. The principal firms are Fox Rothschild LLP - JHU, Kilpatrick Townsend & Stockton LLP - West Coast, and LEYDIG VOIT & MAYER, LTD. The resolved-case volume provides context for the reported metrics, but individual outcomes will depend on claim scope and the application record. The median timing supports early planning for a prolonged prosecution path.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

26.9%
Allow Rate
-33.1% vs TC avg
232
Total Applications
+20.7%
Interview Lift
1620
Avg Prosecution Days
Based on 167 resolved cases, 2023–2026

Rejection Statute Breakdown

31.3%
§101 Eligibility
6.7%
§102 Novelty
23.5%
§103 Obviousness
29.8%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18118528 Classifying User Activity Using Multiple Sensors Final Rejection Samsung Electronics Co., Ltd.
17629327 DETECTING NEURALLY PROGRAMMED TUMORS USING EXPRESSION DATA Final Rejection Genentech, Inc.
18035067 NETWORK APPROACH TO NAVIGATING THE HUMAN GENOME Non-Final OA THE REGENTS OF THE UNIVERSITY OF MICHIGAN
19341734 PLATFORMS, SYSTEMS, AND METHODS FOR PATHWAY OPTIMIZATION FOR PROCESS BOTTLENECKS IN SYNTHETIC BIOLOGY DEVELOPMENT Non-Final OA X Development LLC
18450468 SYSTEMS AND METHODS FOR IDENTIFYING SEQUENCE VARIATION ASSOCIATED WITH GENETIC DISEASES Non-Final OA LIFE TECHNOLOGIES CORPORATION
17842893 CELL-FREE DNA FOR ASSESSING AND/OR TREATING CANCER Final Rejection The Johns Hopkins University
17204892 CELL-FREE DNA FOR ASSESSING AND/OR TREATING CANCER Final Rejection The Johns Hopkins University
17982399 SYSTEMS AND METHODS FOR MULTI-LABEL CANCER CLASSIFICATION Non-Final OA Tempus AI, Inc.
17571412 SYSTEMS AND METHODS FOR JOINT LOW-COVERAGE WHOLE GENOME SEQUENCING AND WHOLE EXOME SEQUENCING INFERENCE OF COPY NUMBER VARIATION FOR CLINICAL DIAGNOSTICS Final Rejection Tempus AI, Inc.
17150992 SYSTEMS AND METHODS FOR MULTI-LABEL CANCER CLASSIFICATION Final Rejection Tempus AI, Inc.
16732229 TRANSCRIPTOME DECONVOLUTION OF METASTATIC TISSUE SAMPLES Final Rejection TEMPUS AI, INC.
17859974 SYSTEM, METHOD, AND APPARATUS FOR PREDICTING GENETIC ANCESTRY Non-Final OA Mars, Incorporated
17590659 System, Method and Computer Simulation Environment For In Silico Trials in Pre-Diabetes and Type 2 Diabetes Final Rejection University of Virginia Patent Foundation
18133798 SYSTEMS AND METHODS FOR GENERATING A GENOTYPIC CAUSAL MODEL OF A DISEASE STATE Non-Final OA KPN INNOVATIONS, LLC.
17725354 Genome Feature Extraction Method, Disease Prediction Method, Apparatus and Device Non-Final OA Alibaba (China) Co., Ltd.
18248529 MULTIPLE INSTANCE LEARNING FOR PEPTIDE-MHC PRESENTATION PREDICTION Non-Final OA NEC Laboratories Europe GmbH
15926977 SYNTHETIC MULTIPLETS FOR MULTIPLETS DETERMINATION Final Rejection Becton, Dickinson And Company
18401532 DETECTION DEVICE AND DETECTION METHOD Final Rejection SHIMADZU CORPORATION
17597760 SYSTEMS AND METHODS FOR CELL OF ORIGIN DETERMINATION FROM VARIANT CALLING DATA Non-Final OA Roche Sequencing Solutions, Inc.
15489658 METHODS FOR DISTINGUISHING INFLAMMATORY BOWEL DISEASES USING MICROBIAL COMMUNITY SIGNATURES Final Rejection UNIVERSITY OF MARYLAND, BALTIMORE
16666210 HIGHLY SENSITIVE TRANSPLANT REJECTION SURVEILLANCE USING TARGETED DETECTION OF DONOR SPECIFIC CELL FREE DNA Non-Final OA The Medical College of Wisconsin, Inc
17502661 METHOD AND APPARATUS FOR PROVIDING INFORMATION ASSOCIATED WITH IMMUNE PHENOTYPES FOR PATHOLOGY SLIDE IMAGE Final Rejection LUNIT Inc.
18556328 MACHINE LEARNING BASED HISTOPATHOLOGICAL RECURRENCE PREDICTION MODELS FOR HPV+ HEAD / NECK SQUAMOUS CELL CARCINOMA Non-Final OA THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
17838115 METHOD AND SYSTEM FOR IMPROVED MANAGEMENT OF GENETIC DISEASES Final Rejection Alexion Pharmaceuticals, Inc.
18311385 Artificial selection approach for improving secondary microbial functions using a partner organism Non-Final OA The Trustees of Boston College
16721619 CELL-FREE DNA END CHARACTERISTICS Final Rejection GRAIL, Inc.
17006124 SYSTEMS AND METHODS FOR DETERMINING CONSENSUS BASE CALLS IN NUCLEIC ACID SEQUENCING Final Rejection GRAIL, LLC
18254534 GENOMIC GRAVE AND FUNERAL SYSTEM FOR CREATION OF GENOMIC GRAVE Non-Final OA Individual inventor

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Kaitlyn L Minchella's allowance rate?

26.9% of resolved applications examined by Kaitlyn L Minchella were allowed (167 resolved cases), compared with 28.0% across Art Unit 1631 over the last five years.

Does an interview help with examiner Kaitlyn L Minchella?

This examiner's interview lift is +20.7 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Kaitlyn L Minchella take to allow a patent?

Applications allowed by Kaitlyn L Minchella took 1,620 days on average from filing to allowance.

Which art unit does examiner Kaitlyn L Minchella work in?

Kaitlyn L Minchella examines applications in Art Unit 1631 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month